Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Sell
7
BCYC Quote, Financials, Valuation and Earnings
Last price:
$9.11
Seasonality move
:
1.89%
Day range:
$9.10 - $9.67
52-week range:
$9.00 - $28.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.01x
P/B ratio:
0.79x
Volume:
258.8K
Avg. volume:
267.9K
1-year change:
-64.8%
Market cap:
$629.7M
Revenue:
$35.3M
EPS (TTM):
-$2.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$7.9M | -$0.82 | -55.59% | -31.65% | $29.55 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$8M | -$0.15 | 4199.24% | -9.44% | $1.93 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -98.11% | $64.50 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
|
VRNA
Verona Pharma PLC
|
$68.4M | -$0.02 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$9.10 | $29.55 | $629.7M | -- | $0.00 | 0% | 15.01x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.29 | $1.93 | $74.4M | -- | $0.00 | 0% | 0.41x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.77 | $17.97 | $1.2M | -- | $0.00 | 0% | 1.60x |
|
NCNA
NuCana PLC
|
$0.79 | $64.50 | $3.1M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.50 | -- | $256.5K | -- | $0.25 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$66.81 | $81.00 | $5.7B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | 0.789 | -- | 13.61x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 2.439 | 20.51% | 3.54x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.756 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 0.645 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.548 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | -0.759 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$67.1M | -25.48% | -26.21% | -1426.21% | -$9.8M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Bicycle Therapeutics PLC vs. Competitors
-
Which has Higher Returns BCYC or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of -43.07%. Bicycle Therapeutics PLC's return on equity of -26.21% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About BCYC or ADAP?
Bicycle Therapeutics PLC has a consensus price target of $29.55, signalling upside risk potential of 224.68%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.93 which suggests that it could grow by 561.97%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 ADAPAdaptimmune Therapeutics PLC2 2 0 -
Is BCYC or ADAP More Risky?
Bicycle Therapeutics PLC has a beta of 1.121, which suggesting that the stock is 12.137% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.520, suggesting its more volatile than the S&P 500 by 152.023%.
-
Which is a Better Dividend Stock BCYC or ADAP?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or ADAP?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Bicycle Therapeutics PLC's net income of -$51.9M is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 15.01x versus 0.41x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC15.01x -- $3.7M -$51.9M ADAPAdaptimmune Therapeutics PLC0.41x -- $40.9M -$17.6M
-
Which has Higher Returns BCYC or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -26.21% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About BCYC or BDRX?
Bicycle Therapeutics PLC has a consensus price target of $29.55, signalling upside risk potential of 224.68%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 922.13%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is BCYC or BDRX More Risky?
Bicycle Therapeutics PLC has a beta of 1.121, which suggesting that the stock is 12.137% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.
-
Which is a Better Dividend Stock BCYC or BDRX?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or BDRX?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$51.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 15.01x versus 1.60x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC15.01x -- $3.7M -$51.9M BDRXBiodexa Pharmaceuticals PLC1.60x -- -- --
-
Which has Higher Returns BCYC or NCNA?
NuCana PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -26.21% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About BCYC or NCNA?
Bicycle Therapeutics PLC has a consensus price target of $29.55, signalling upside risk potential of 224.68%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 8068.69%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 NCNANuCana PLC1 1 0 -
Is BCYC or NCNA More Risky?
Bicycle Therapeutics PLC has a beta of 1.121, which suggesting that the stock is 12.137% more volatile than S&P 500. In comparison NuCana PLC has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.789%.
-
Which is a Better Dividend Stock BCYC or NCNA?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or NCNA?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are larger than NuCana PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$51.9M is lower than NuCana PLC's net income of -$5.9M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 15.01x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC15.01x -- $3.7M -$51.9M NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns BCYC or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -26.21% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About BCYC or TCBP?
Bicycle Therapeutics PLC has a consensus price target of $29.55, signalling upside risk potential of 224.68%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 9500%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is BCYC or TCBP More Risky?
Bicycle Therapeutics PLC has a beta of 1.121, which suggesting that the stock is 12.137% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BCYC or TCBP?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or TCBP?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$51.9M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 15.01x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC15.01x -- $3.7M -$51.9M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
-
Which has Higher Returns BCYC or VRNA?
Verona Pharma PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of -92.29%. Bicycle Therapeutics PLC's return on equity of -26.21% beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About BCYC or VRNA?
Bicycle Therapeutics PLC has a consensus price target of $29.55, signalling upside risk potential of 224.68%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 21.24%. Given that Bicycle Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 VRNAVerona Pharma PLC5 0 0 -
Is BCYC or VRNA More Risky?
Bicycle Therapeutics PLC has a beta of 1.121, which suggesting that the stock is 12.137% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.
-
Which is a Better Dividend Stock BCYC or VRNA?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or VRNA?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Bicycle Therapeutics PLC's net income of -$51.9M is lower than Verona Pharma PLC's net income of -$33.8M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 15.01x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC15.01x -- $3.7M -$51.9M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
